Author + information
- Aarif Y. Khakoo, MDa,∗ (, )
- Nicole R. Yurgin, PhDb,
- Paul R. Eisenberg, MD, MPHc and
- Gregg C. Fonarow, MDd
- aTranslational Medicine, Amgen, Inc., South San Francisco, California
- bUS Medical, Amgen, Inc., South San Francisco, California
- cAmgen, Inc., South San Francisco, California
- dAhmanson-UCLA Cardiomyopathy Center, UCLA Division of Cardiology, Geffen School of Medicine at UCLA, Los Angeles, California
- ↵∗Address for correspondence:
Dr. Aarif Y. Khakoo, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080.
Despite the fact that cardiovascular disease (CVD) is the number 1 cause of death globally, investment in drug development and new drug approvals for CVD are precipitously declining. In contrast, the trajectory of both investment in development as well as new drug approvals for oncology have been increasing steadily over the same time frame. The factors that have spurred drug development in oncology may be applicable to new efforts to overcome barriers to drug development for CVD. Greater investment in basic research and application of expedited regulatory pathways have contributed to a lowering of development barriers in oncology. Barriers in implementation are also critical. More rapid adoption of guideline-based therapies and lower access barriers by payers have contributed to fewer implementation barriers for oncology therapeutics. There is substantially greater advocacy among patients and physicians for new oncology therapeutics, and such advocacy efforts are likely to have had a meaningful impact on lowering barriers to develop new oncology therapeutics. Broad support of patient and physician advocacy efforts directed towards CVD may help overcome existing development and implementation barriers to new drug development, thereby spurring more rapid progress in the fight to eradicate cardiovascular disease.
Drs. Khakoo and Yurgin are employees and shareholders of Amgen, Inc. Dr. Eisenberg is a former employee of and a shareholder of Amgen. Dr. Fonorow has received grants from the National Institutes of Health; and personal fees from Amgen, Bayer, AstraZeneca, Abbott, Novartis, Janssen, and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and U.S. Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received January 17, 2019.
- Accepted January 20, 2019.
- 2019 The Authors